ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

New antiviral agents for the treatment of hepatitis C: ABT-450

(2014) Andres F Carrion et al.   EXPERT OPINION ON PHARMACOTHERAPY

Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

(2014) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

(2014) Jordan J. Feld et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1

(2014) Kris V. Kowdley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma

(2013) Rebecca L. Morgan et al.   ANNALS OF INTERNAL MEDICINE

Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: A longitudinal analysis

(2013) Mazen Noureddin et al.   HEPATOLOGY

Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis

(2013) Adriaan J. van der Meer et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890

(2013) Christophe Hézode et al.   JOURNAL OF HEPATOLOGY

Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response

(2013) John M. Vierling et al.   JOURNAL OF HEPATOLOGY

Epidemiology and natural history of HCV infection

(2013) Behzad Hajarizadeh et al.   Nature Reviews Gastroenterology & Hepatology

Chronic hepatitis C virus (HCV) disease burden and cost in the United States

(2012) Homie Razavi et al.   HEPATOLOGY

Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence

(2012) Khayriyyah Mohd Hanafiah et al.   HEPATOLOGY

A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis C

(2011) Lisa I. Backus et al.   Clinical Gastroenterology and Hepatology

Future treatment of patients with HCV cirrhosis

(2011) Marc Bourlière et al.   LIVER INTERNATIONAL

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

(2011) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

(2011) Kenneth E. Sherman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

(2011) Bruce R. Bacon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Retreatment of HCV Infection

(2011) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

(2011) Ira M. Jacobson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evolving epidemiology of hepatitis C virus

(2010) D. Lavanchy   CLINICAL MICROBIOLOGY AND INFECTION

Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study

(2010) Savino Bruno et al.   HEPATOLOGY

The metabolism and disposition of a potent inhibitor of hepatitis C virus NS3/4A protease

(2010) E. Monteagudo et al.   XENOBIOTICA

Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression

(2009) Gary L. Davis et al.   GASTROENTEROLOGY

Effect of hepatitis C virus and its treatment on survival

(2009) Adeel A. Butt et al.   HEPATOLOGY